Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead

Group 1: Duquesne Family Office's Investment Activity - Duquesne Family Office's chief, Stanley Druckenmiller, completely exited his stake in Palo Alto Networks, a prominent stock-split stock, during the March-ended quarter [7][12] - Druckenmiller sold all 87,424 shares of Palo Alto Networks, which had completed a 2-for-1 stock split in December [12] - The decision to sell may have been influenced by Palo Alto's high valuation at 60 times forecast earnings per share in 2025, despite its strong growth [13] Group 2: Palo Alto Networks Performance - Palo Alto Networks reported a 34% increase in annual recurring revenue for its next-generation security solutions, reaching $5.1 billion [14] - The company's total backlog of remaining performance obligations grew by 19% to $13.5 billion year-over-year [14] - The shift to a cloud-based cybersecurity model has resulted in 80% of net sales coming from higher-margin subscriptions and support services [15] Group 3: Teva Pharmaceutical Industries Investment - Druckenmiller has consistently increased his stake in Teva Pharmaceutical, purchasing 5,882,350 shares in the March-ended quarter, following previous purchases of 1,427,950 and 7,569,450 shares [18] - Teva has shifted focus towards novel-drug development, with the tardive dyskinesia drug Austedo showing 39% constant-currency sales growth in the latest quarter [21] - Teva's net debt has significantly decreased from over $35 billion post-Actavis acquisition to less than $15 billion as of March 2025 [22] Group 4: Teva's Legal and Financial Recovery - Teva resolved its opioid litigation issues with a $4.25 billion settlement approved by 48 of the 50 U.S. states, allowing for improved financial stability [23] - The stock is currently valued at just 6.6 times forecast earnings per share in 2025, indicating a deep-discount valuation compared to the broader market [24] - Teva has achieved year-over-year sales growth for nine consecutive quarters, reflecting a positive trend in its brand-name therapies [25]